Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance (palbociclib) Read more
eFFECTOR Enters Into Agreement with Pfizer to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types Read more
Iovance and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement Read more
Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases Read more
Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat technology Read more